ISIS & ASCO

ISIS & ASCO APO & CRP:  Blockbuster Alphabet Soup for ISIS? Among its broad and deep R&D pipeline, ISIS has two potential home run compounds with important Phase II clinical data due by mid-year – each addressing multiple blockbuster drug markets.  In our view, a  successful result from either candidate is likely to establish ISIS’[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.